Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

(Reuters) – Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Read more…